Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1691 4100
This examiner grants 52% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19539493 | Compounds with Anti-KRAS Mutated Tumor Activity | Non-Final OA | Trasveda Ltd. |
| 18556081 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17775100 | EFFECTIVE INTRANASAL DELIVERY TO BRAIN | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18145595 | UREA INHIBITORS OF MICRO-RNA | Non-Final OA | Board of Regents, The University of Texas System |
| 18274560 | METHODS FOR INHIBITING CORONAVIRUSES USING SULFORAPHANE | Non-Final OA | The Johns Hopkins University |
| 18007822 | METHODS OF TREATING A CORONAVIRUS INFECTION | Non-Final OA | The General Hospital Corporation |
| 18376498 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Non-Final OA | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization |
| 18274565 | REACTIVATION OF EMBRYONIC AND FETAL HEMOGLOBIN | Non-Final OA | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy